Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 69,487,852 *
Stock purchase warrants 500,000 **
Stock options 11,301,266 **
Fully diluted 78,764,223**
Cash  $75 million*
Debt Nil**
Trading symbol AVXL
52-week range $28.70 – $2.20*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org
* As of February 11, 2021

** As of December 31, 2020

Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)